Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

60 Degrees Pharmaceuticals (SXTP)

60 Degrees Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SXTP
DateTimeSourceHeadlineSymbolCompany
08/01/202513:02GlobeNewswire Inc.60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) BabesiosisNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
23/12/202413:57GlobeNewswire Inc.Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and PreventionNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
11/12/202413:56GlobeNewswire Inc.60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women’s HospitalNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
14/11/202419:31GlobeNewswire Inc.60 Degrees Pharmaceuticals Announces Third Quarter 2024 ResultsNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
03/10/202413:02GlobeNewswire Inc.60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. LaunchNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
06/09/202412:59GlobeNewswire Inc.60 Degrees Pharmaceuticals, Inc. Announces Closing of $4 Million Private Placement Priced At-the-Market Under Nasdaq RulesNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
04/09/202412:00GlobeNewswire Inc.60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq RulesNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
28/08/202419:59Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
28/08/202418:48GlobeNewswire Inc.60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing RequirementsNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
14/08/202419:55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
14/08/202415:01GlobeNewswire Inc.60 Degrees Pharmaceuticals Announces Second Quarter 2024 ResultsNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
14/08/202414:29Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SXTP60 Degrees Pharmaceuticals Inc
12/08/202416:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
12/08/202413:12GlobeNewswire Inc.60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb StudyNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
06/08/202413:26GlobeNewswire Inc.60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock SplitNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
02/08/202420:15Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SXTP60 Degrees Pharmaceuticals Inc
26/07/202420:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
26/07/202417:21Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SXTP60 Degrees Pharmaceuticals Inc
25/07/202413:02GlobeNewswire Inc.60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade SupportNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
24/07/202421:05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SXTP60 Degrees Pharmaceuticals Inc
22/07/202415:23Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SXTP60 Degrees Pharmaceuticals Inc
19/07/202412:29GlobeNewswire Inc.60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis StudyNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
19/07/202404:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
16/07/202421:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
12/07/202421:02Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:SXTP60 Degrees Pharmaceuticals Inc
09/07/202419:37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
09/07/202410:31GlobeNewswire Inc.60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior TreatmentNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
27/06/202411:59GlobeNewswire Inc.First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its KindNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
11/06/202411:59GlobeNewswire Inc.60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute BabesiosisNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
30/05/202411:59GlobeNewswire Inc.Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its KindNASDAQ:SXTP60 Degrees Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:SXTP